The Hospital of the University of Pennsylvania
Enrolling Patients in Clinical Trial for
Treating Idiopathic Pulmonary Fibrosis
(Philadelphia, PA) – The Hospital of the University of
Pennsylvania (HUP) is seeking participants in an international,
Phase 3 clinical trial, called the INSPIRE Trial. This randomized, double-blind,
placebo-controlled research study will evaluate the therapeutic potential
of interferon gamma-1b – a manufactured version of a naturally occurring
human protein that stimulates the immune system – in the treatment
of Idiopathic Pulmonary Fibrosis (IPF). IPF is a debilitating and potentially
deadly lung disease affecting more than 80,000 people in the United States.
HUP is one of 75 leading medical centers in North America and Europe participating
in the INSPIRE Trial.
IPF is a disease characterized by progressive scarring (fibrosis) of the
lungs. Symptoms include a progressively worsening shortness of breath
(dyspnea), which makes it difficult to perform routine tasks, such as
walking. Ultimately the loss of lung function leads to death. The cause
of IPF is unknown, and currently there is no FDA-approved treatment for
this fatal disease.
Investigators hope to enroll 12 participants in the Delaware Valley and
a total of 600 patients around the world will be enrolled. Adults with
IPF may be eligible to participate in the INSPIRE Trial if they are between
the ages of 40 and 79, have been diagnosed within the past 36 months,
and meet trial eligibility requirements. Those enrolled will receive either
the investigational study drug or placebo by subcutaneous injection three
times a week for a minimum of two years. For more information on the trial
and eligibility, contact the study’s research coordinator, Susan
Metzger, MSN, RN, at 215.662.3115 or via e-mail at email@example.com.
You can also visit the trial’s web site at www.inspiretrial.com
for more information.
PENN Medicine is a $2.7 billion enterprise dedicated
to the related missions of medical education, biomedical research, and
high-quality patient care. PENN Medicine consists of the University of
Pennsylvania School of Medicine (founded in 1765 as the nation’s
first medical school) and the University of Pennsylvania Health System
(created in 1993 as the nation’s first integrated academic health
Penn’s School of Medicine is ranked #3 in the nation for receipt
of NIH research funds; and ranked #4 in the nation in U.S. News &
World Report’s most recent ranking of top research-oriented medical
schools. Supporting 1,400 fulltime faculty and 700 students, the School
of Medicine is recognized worldwide for its superior education and training
of the next generation of physician-scientists and leaders of academic
Penn Health System is comprised of: its flagship hospital, the Hospital
of the University of Pennsylvania, consistently rated one of the nation’s
“Honor Roll” hospitals by U.S. News & World Report; Pennsylvania
Hospital, the nation's first hospital; Presbyterian Medical Center; a
faculty practice plan; a primary-care provider network; two multispecialty
satellite facilities; and home health care and hospice.